Effect of pravastatin in the treatment of patients with type III hyperlipoproteinemia

American Journal of Therapeutics

Volumn 3, Issue 11, 1996, Pages 755-762

  Knopp, Robert H ^a   Illingworth, D Roger ^b   Stein, Evan A ^c   Ginsberg, Henry N ^d   Broyles, Frances E ^a   Behounek, Bruce D ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Cholesterol Center   (United States)

^d New York Presbyterian Hospital Columbia University Medical Center   (United States)

^e BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

pravastatin; Type III hyperlipoproteinemia

Indexed keywords

APOLIPOPROTEIN E2; CHOLESTEROL; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0030424665     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199611000-00004     Document Type: Article

References (44)

1. Hazzard WR: Primary Type III hyperlipoproteinemia. In Hyperlipidemia: Diagnosis and Therapy (Eds. Rifkind BM, Levy RI), Grune and Stratton, New York, 1977, pp 137-175.
2. Mahley RW: Atherogenic lipoproteins and coronary artery disease: concepts derived from recent advances in cellular and molecular biology. Circulation 1985;72:943-948.
3. Mahley RW, Rall SC: Type III hyperlipoproteinemia. In The Metabolic Basis of Inherited Disease, 6th ed. (Eds. Scriver CR, Beaudet AL, Sly WS, Valle D), McGraw Hill, New York, 1989, pp. 1195-1213.
4. Mahley RW, Angelin B: Type III hyperlipoproteinemia: recent insights into the genetic defect of familial dysbetalipoproteinemia. Adv Intern Med. 1984;29:385-411.
5. Schaefer EJ: Dietary and drug treatment, (pp. 633-637). In Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. (Moderator Brewer HB Jr.) Ann Intern Med 1983;98:623-640.
6. Knopp RH, Walden CE, Heiss G, Johnson JL, Wahl PW: Prevalence and clinical correlates of beta migrating VLDL: The Lipid Research Clinics Program Prevalence Study. Am J Med 1986;81:493-502.
7. Illingworth DR: Fibric acid derivatives. In Drug Treatment of Hyperlipidemia (Ed. Rifkin BM), Marcel Dekker Inc, New York, 1991, pp. 103-138.
8. Vega GL, Krauss RM, Grundy SM: Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J Intern Med 1990;227:81-94.
9. The Expert Panel: Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36-69.
10. 2+ precipitation procedure for quantification of highdensity lipoprotein cholesterol. Clin Chem 1982;28:1379-1388.
11. Warnick GR: Enzymatic methods for quantification of lipoprotein lipids. In Methods in Enzymology, vol. 129, Plasma Lipoproteins, Part B, Characterization, Cell Biology and Metabolism (Eds. Albers JJ, Segrest JP), Academic Press Inc, New York, 1986, pp. 101-123.
12. Lipid Research Clinics Program: Manual of Laboratory Operations, vol. 1, DHEW publication no. (HIH)75-628, National Institutes of Health, Bethesda, MD, 1974.
13. Rall SC Jr, Weisgraber KH, Mahley RW: Isolation and characterization of apolipoprotein E. In Methods in Enzymology, vol. 128 (Eds. Segrist JP, Albers JJ), Academic Press Inc, Orlando, 1986, pp. 273-87.
14. East CA, Grundy SM, Bilheimer DW: Preliminary report: treatment of Type 3 hyperlipoproteinemia with mevinolin. Metabolism 1986;35:97-98.
15. Vega GL, East C, Grundy SM: Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B. Atherosclerosis 1988;70:131-143.
16. Stuyt PMJ, Mol MJTM, Stalenhoef AFH, Demacker PNM, van 't Laar A: Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (Type III hyperlipoproteinemia). Am J Med 1990; 88(1N):42N-45N.
17. Illingworth DR, O'Malley JP: The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia. Metabolism 1990;39:403-409.
18. Feussner G, Eichinger M, Ziegler R: The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with Type III hyperlipoproteinemia. Clin Invest 1992;70:1027-1035.
19. Davignon J, Roederer G, Montigny M, Hayden MR, Tan M-H, Connelly PW, et al: Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 1994;73: 339-345.
20. Wiklund O, Angelin B, Bergman M, Berglund L, Bondjers G, Carlsson A, et al.: Pravastatin and gemfibrozil alone and in combination in the treatment of hypercholesterolemia. Am J Med 1993;94:13-20.
21. Athyros VG, Papageorgiou AA, Hagikonstantinou HJ, Papadopoulos GV, Zamboulis CX, Kontopoulos AG: Combined treatment with pravastatin and gemfibrozil in patients with refractory familial combined hyperlipidaemia: a clinical study. Drug Invest 1994;7:134-142.
22. Hunninghake DB, Knopp RH, Shonfeld G, Goldberg AC, Brown WV, Schaefer EJ, et al.: Efficacy and safety of pravastatin in patients with primary hypercholesterolemia, I: a dose-response study. Atherosclerosis 1990;85:81-89.
23. Hunninghake DB, Mellies MJ, Goldberg AC, Kuo PT, Kostis JB, Schrott HG, et al.: Efficacy and safety of pravastatin in patients with primary hypercholesterolemia, II: once-daily versus twice-daily dosing. Atherosclerosis 1990;85:219-227.
24. Knopp RH, Brown WV, Corder C, Dobs AS, Dujovne CA, Goldberg AC, Hunninghake DB, Insull W Jr., Mellies MJ, Smith DA, Stein EA: Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Arch Int Med 1993; 153:1321-1329.
25. Knopp RH, Walden CE, Heiss G, Johnson JL, Wahl PW: Prevalence and clinical correlates of beta migrating VLDL: The Lipid Research Clinics Program Prevalence Study. Am J Med 1986;81:493-502.
26. Vega GL, East C, Grundy SM: Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B. Atherosclerosis 1988;70:131-143.
27. Mabuchi H, Kamon N, Fujita H, Michishita I, Takeda M, Kajinami K, Ito H, Wakasugi T, Takeda R: Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with FH. Metabolism 1987;36(5):475-479.
28. Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH: Effect of fluvastatin on intermediate-density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. Am J Cardiol, In press.
29. Howard BV, Howard WJ: Dyslipidemia in non-insulin dependent diabetes mellitus. Endo Rev. 1994;15:263-274.
30. Nestel PJ, Fidge NH, Tan MH: Increased lipoprotein remnant formation in chronic renal failure. N Engl J Med 1982;307(6):329-333.
31. Chait A, Albers JJ, Brunzell JD: Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia. Eur J Clin Invest 1980;10:17-22.
32. Jones HB, Gofman JW, Lindgren FT, et al: Lipoproteins in atherosclerosis. Am J Med 1951:358-380.
33. Gofman JW, Young W, Tandy R: Ischemic heart disease, atherosclerosis and longevity. Circulation 1966;34:679-697.
34. Tatami R, Mabuchi H, Ueda K, et al: Intermediate-density lipoprotein and cholesterol-rich VLDL in angiographically determined coronary artery disease. Circulation 1981;64:1174-1183.
35. Steiner G, Schwartz L, Shumak S, Poapst M: The association of increased levels of IDL with smoking and with coronary artery disease. Circulation 1987;75:124-130.
36. Krauss RM, Williams PT, Brensike J, et al: Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolemic men. Lancet 1987(2):62-65.
37. Hodis HN, Mack WJ, Azen SP, et al: Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42-49.
38. McTavish D, Sorkin EM: Pravastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1991;42:65-89.
39. Jones PH, Farmer JA, Cressman MD, McKenney JM, Wright JT, Proctor JD, et al: Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin Cardiol 1991;14:146-151.
40. Rubenfire M, Maciejko JJ, Blevins RD, Orringer C, Kobylak L, Rosman H, for the Southeastern Michigan Collaborative Group: The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. Arch Intern Med 1991;151:2234-2240.
41. Wiklund O, Angelin B, Fager G, Eriksson M, Olofsson S-O, Berglund L, et al.: Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. J Intern Med 1990;228:241-247.
42. Goto Y, Yasugi T, Goto Y, et al.: Clinical evaluation of CS-514 (pravastatin) on hyperlipidemia: double-blind study with clinofibrate [in Japanese, with English abstract]. Clin Eval 1988;16:211-249.
43. Behounek BD, McGovern ME, Kassler-Taub KB, Markowitz JS, Bergman M, for the Pravastatin Multinational Study Group for Cardiac Risk Patients: Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol liter (200 to 300 mg dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72: 1031-1037.
44. Furberg CD, Byington RP, Crouse JR, Espeland MA: Pravastatin, lipids, and major coronary events. Am J Cardiol 1994;73(15):1133-1134.